CN106999539A - 腹水的治疗 - Google Patents

腹水的治疗 Download PDF

Info

Publication number
CN106999539A
CN106999539A CN201680003239.1A CN201680003239A CN106999539A CN 106999539 A CN106999539 A CN 106999539A CN 201680003239 A CN201680003239 A CN 201680003239A CN 106999539 A CN106999539 A CN 106999539A
Authority
CN
China
Prior art keywords
terlipressin
ascites
patient
continuous infusion
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680003239.1A
Other languages
English (en)
Chinese (zh)
Inventor
P.昂厄利
P.马卡姆
J.阿达姆斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biovie Inc
Original Assignee
Nanoantibiotics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57609113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN106999539(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nanoantibiotics Inc filed Critical Nanoantibiotics Inc
Priority to CN202510468211.6A priority Critical patent/CN120324576A/zh
Publication of CN106999539A publication Critical patent/CN106999539A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
CN201680003239.1A 2015-06-30 2016-06-30 腹水的治疗 Pending CN106999539A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510468211.6A CN120324576A (zh) 2015-06-30 2016-06-30 腹水的治疗

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562186638P 2015-06-30 2015-06-30
US62/186,638 2015-06-30
US201562267510P 2015-12-15 2015-12-15
US62/267,510 2015-12-15
US201662321558P 2016-04-12 2016-04-12
US62/321,558 2016-04-12
PCT/US2016/040284 WO2017004317A1 (en) 2015-06-30 2016-06-30 Treatment of ascites

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510468211.6A Division CN120324576A (zh) 2015-06-30 2016-06-30 腹水的治疗

Publications (1)

Publication Number Publication Date
CN106999539A true CN106999539A (zh) 2017-08-01

Family

ID=57609113

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680003239.1A Pending CN106999539A (zh) 2015-06-30 2016-06-30 腹水的治疗
CN202510468211.6A Pending CN120324576A (zh) 2015-06-30 2016-06-30 腹水的治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510468211.6A Pending CN120324576A (zh) 2015-06-30 2016-06-30 腹水的治疗

Country Status (7)

Country Link
US (6) US9655945B2 (enExample)
EP (2) EP4338795A3 (enExample)
JP (6) JP2017014206A (enExample)
CN (2) CN106999539A (enExample)
ES (1) ES2971959T3 (enExample)
HK (1) HK1258611A1 (enExample)
WO (1) WO2017004317A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112704727A (zh) * 2021-01-12 2021-04-27 重庆医科大学附属第二医院 特利加压素在制备动力性肠梗阻药物中的应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ591810A (en) 2008-09-17 2012-12-21 Chiasma Inc Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
HRP20220225T1 (hr) 2014-10-24 2022-04-29 Mallinckrodt Pharmaceuticals Ireland Limited Terlipresin za liječenje hepatorenalnog sindroma tip 1
PL3253401T3 (pl) 2015-02-03 2025-08-04 Amryt Endo, Inc. Leczenie akromegalii oktreotydem doustnym
JP2017014206A (ja) * 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療
IL265761B2 (en) 2016-10-21 2024-11-01 Amryt Endo Inc Oral terlipressin compositions for use in treatment of ascites
CN113077888A (zh) * 2021-03-30 2021-07-06 福州宜星大数据产业投资有限公司 自动化meld评分方法、终端及存储介质
EP4472653A4 (en) * 2022-02-03 2025-11-26 Biovie Inc METHODS OF TREATING A DISEASE WITH TERLIPRESSIN

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024213A2 (en) * 2000-09-15 2002-03-28 Inserm Improved protocol for paracentesis
US20110300109A1 (en) * 2008-08-26 2011-12-08 Kyon Biotech Ag Compositions and methods for treating cancer
CN102731625A (zh) * 2012-06-27 2012-10-17 深圳翰宇药业股份有限公司 一种纯化特利加压素的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1984012B1 (en) * 2006-02-13 2015-12-30 Ferring B.V. Use of peptidic vasopressin receptor agonists
WO2009037586A2 (en) * 2007-08-14 2009-03-26 Ferring B.V. Use of peptidic vasopressin receptor agonists
US20100311642A1 (en) * 2007-09-28 2010-12-09 Ferring B.V. Use of v2 receptor antagonists in combination with vaso pressinergic agnosts
BRPI0819434A2 (pt) * 2007-11-08 2019-09-24 Univ Utah Res Found método de tratamento ou prevenção de doenças hepáticas e uso de antagonistas á angiogênese em condições de proliferação venosa anormal
CN105132395A (zh) * 2009-03-09 2015-12-09 生物蛋白有限公司 Mirac蛋白
JP5749255B2 (ja) * 2009-06-08 2015-07-15 ユーシーエル ビジネス ピーエルシー Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復
BR112013000744A2 (pt) * 2010-07-14 2020-07-14 Cumberland Emerging Technologies, Inc uso de um antagonista de receptor de tromboxana a2 para prevenção ou tratamento de síndrome hepatorrenal,encefalopatia hepática,e doenças associadas
WO2013106072A1 (en) 2012-01-10 2013-07-18 Sorbent Therapeutics, Inc. Compositions comprising crosslinked cation-binding polymers and uses thereof
JO3109B1 (ar) 2012-05-10 2017-09-20 Ferring Bv منبهات لمستقبلات v1a
JP6378194B2 (ja) * 2012-11-12 2018-08-22 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト 慢性肝疾患の評価のための疾患重症度指数および原発性硬化性胆管炎の３つの異なるサブタイプの診断方法
JP6522584B2 (ja) * 2013-04-26 2019-05-29 ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ 腎不全を処置するための組成物及び方法
CN104510840A (zh) 2013-08-21 2015-04-15 乔治亚摄政研究学院有限公司 改性绿茶多酚和其用于治疗肝病的方法
JP2017014206A (ja) * 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024213A2 (en) * 2000-09-15 2002-03-28 Inserm Improved protocol for paracentesis
US20040102362A1 (en) * 2000-09-15 2004-05-27 Didier Lebrec Protocol for paracentesis
US20110300109A1 (en) * 2008-08-26 2011-12-08 Kyon Biotech Ag Compositions and methods for treating cancer
CN102731625A (zh) * 2012-06-27 2012-10-17 深圳翰宇药业股份有限公司 一种纯化特利加压素的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALEKSANDER KRAG等: ""Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome"", 《HEPATOLOGY》 *
MARCUS ROBERTSON等: ""Continuous outpatient terlipressin infusion for hepatorenal syndrome as a bridge to successful liver transplantation"", 《HEPATOLOGY》 *
PAOLO ANGELI: ""Terlipressin for the treatment of hepatorenal syndrome in patients with cirrhosis"", 《EXPERT OPINION ON ORPHAN DRUGS》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112704727A (zh) * 2021-01-12 2021-04-27 重庆医科大学附属第二医院 特利加压素在制备动力性肠梗阻药物中的应用
CN112704727B (zh) * 2021-01-12 2023-05-16 重庆医科大学附属第二医院 特利加压素在制备动力性肠梗阻药物中的应用

Also Published As

Publication number Publication date
JP2025143324A (ja) 2025-10-01
EP3347032A4 (en) 2019-06-19
HK1258611A1 (zh) 2019-11-15
US20250312410A1 (en) 2025-10-09
JP2020172520A (ja) 2020-10-22
JP2018172440A (ja) 2018-11-08
WO2017004317A1 (en) 2017-01-05
US20170000844A1 (en) 2017-01-05
US20180000887A1 (en) 2018-01-04
CN120324576A (zh) 2025-07-18
US20230146264A1 (en) 2023-05-11
US20240165193A1 (en) 2024-05-23
EP3347032A1 (en) 2018-07-18
ES2971959T3 (es) 2024-06-10
US9655945B2 (en) 2017-05-23
JP2017014206A (ja) 2017-01-19
JP2023160839A (ja) 2023-11-02
JP2022136104A (ja) 2022-09-15
EP4338795A2 (en) 2024-03-20
EP3347032B1 (en) 2023-11-29
US11364277B2 (en) 2022-06-21
US20190365848A1 (en) 2019-12-05
EP4338795A3 (en) 2024-08-28

Similar Documents

Publication Publication Date Title
CN106999539A (zh) 腹水的治疗
JP2020143143A (ja) 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法
JP2018521964A5 (enExample)
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
JP2025143324A5 (enExample)
JP2018531605A5 (enExample)
JP2020510043A5 (enExample)
Saraceno et al. Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: a report of two cases
US20210220379A1 (en) Peritoneal sodium-glucose transporter (sglt) inhibitors for improvement of peritoneal dialysis
CN102552121B (zh) 一种米力农注射液
CN114796246B (zh) 一种用于治疗心力衰竭的药物及其用途
CN104688766B (zh) 注射用藻酸双酯钠粉针剂药物组合物和制法
RU2406539C2 (ru) Способ лечения хронической почечной недостаточности
CN1064234C (zh) 二咖啡酰氧基--奎宁酸在制药中的应用
Poca et al. 104 RENAL FAILURE AND MORTALITY IN CIRRHOTIC PATIENTS WITH SPONTANEOUS BACTERIAL PERITONITIS AND LOW RISK OF MORTALITY NON-TREATED WITH ALBUMIN
Zhao A Case Analysis of Antihypertensive Treatment in a Patient Undergoing CRRT with Comorbid Coronary Heart Disease
WO2016139740A1 (ja) 肝線維化改善剤
Mckellar et al. Hyperkalaemia: causes, electrocardiographic changes and management
Knyazkova et al. Efficiency of torasemide in heart failure in patients with ischemic heart disease and chronic obstructive pulmonary disease
US20170007617A1 (en) Intravenous formulations of a late sodium current inhibitor
Alessandria et al. 103 RELATIVE ADRENAL INSUFFICIENCY IN CIRRHOSIS: RELEVANCE IN PATIENTS WITH ASCITES AND TREATMENT WITH HYDROCORTISONE IN REFRACTORY ASCITES
CN108567768B (zh) 对-[(二丙氨基)磺酰基]苯甲酸的医药用途
CN103285378A (zh) Glp-1用于制备预防与治疗2型糖尿病性心肌病的药物的用途
Li Application of albumin in liver cirrhosis and its complications
CN102579325A (zh) 乙烷硒啉静脉注射剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20170801

RJ01 Rejection of invention patent application after publication